Bayer Schering acquires Japanese Alzheimer's imaging agents
This article was originally published in Scrip
Executive Summary
Bayer Schering Pharmahas licensed from the University of Nagasaki in Japan a series of molecules for use in the positron emission tomography imaging and diagnosis of Alzheimer's disease. The fluorine-18-labelled tracers bind to amyloid beta protein, the accumulation of which has been linked to the development of the disorder. At present, a diagnosis can only be confirmed through autopsy; the molecular imaging agents may enable much earlier detection and treatment, said the company, which holds exclusive global development and marketing rights.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.